Cell Growth & Differentiation, Vol 8, Issue 8 903-911, Copyright © 1997 by American Association of Cancer Research

ARTICLES

Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells

A deFazio, YE Chiew, M McEvoy, CK Watts and RL Sutherland
Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.

In human breast cancer, progression to a more malignant phenotype is often accompanied by decreased expression of estrogen receptor (ER) and increased expression of epidermal growth factor receptor (EGFR). Higher levels of this receptor tyrosine kinase are found in tumors lacking ER, and a quantitative, inverse relationship exists between the level of ER and EGFR mRNA in human breast cell lines. Antisense ER (ASER) RNA was used to evaluate the consequence of decreased ER expression in breast cancer cells, specifically to determine whether ER is involved in the regulation of EGFR gene expression. ER-positive MCF-7 human breast cancer cells were transfected with ASER, and clones constitutively expressing ASER RNA had decreased ER and up to a 3-fold increase in the expression of EGFR mRNA. To confirm that this observation was a direct consequence of ASER expression, a metal-inducible ASER expression construct was transfected into MCF-7 cells, and transfected clones were isolated and characterized. Northern analysis revealed an induction of ASER RNA within 1 h of the addition of zinc, which was followed by a 4-fold increase in EGFR mRNA levels, maximal at 6-12 h. The basal level of expression of the glucocorticoid receptor is also inversely related to that of ER among breast cancer cell lines, but neither constitutive nor inducible expression of ASER affected the expression of glucocorticoid receptor. These data support the hypothesis that the level of expression of ER specifically influences the expression of EGFR in human breast cancer cells and provides a potential link between loss of steroid sensitivity and the acquisition of autonomous growth.

This article has been cited by other articles:

				X. Qi, J. Tang, M. Loesch, N. Pohl, S. Alkan, and G. Chen p38{gamma} Mitogen-Activated Protein Kinase Integrates Signaling Crosstalk between Ras and Estrogen Receptor to Increase Breast Cancer Invasion. Cancer Res., August 1, 2006; 66(15): 7540 - 7547. [Abstract] [Full Text] [PDF]

				R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641. [Abstract] [Full Text] [PDF]

				R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S. [Abstract] [Full Text] [PDF]

				J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro Endocrinology, November 1, 2003; 144(11): 5105 - 5117. [Abstract] [Full Text] [PDF]

				D. K. Biswas, K. J. Martin, C. McAlister, A. P. Cruz, E. Graner, S.-c. Dai, and A. B. Pardee Apoptosis Caused by Chemotherapeutic Inhibition of Nuclear Factor-{kappa}B Activation Cancer Res., January 15, 2003; 63(2): 290 - 295. [Abstract] [Full Text] [PDF]

				R. I. NICHOLSON, I. R. HUTCHESON, M. E. HARPER, J. M. KNOWLDEN, D. BARROW, R. A. McCLELLAND, H. E. JONES, A. E. WAKELING, and J.M. W. GEE Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 104 - 115. [Abstract] [Full Text] [PDF]

				A. T. Baron, J. M. Lafky, V. J. Suman, D. W. Hillman, M. C. Buenafe, C. H. Boardman, K. C. Podratz, E. A. Perez, and N. J. Maihle A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1175 - 1185. [Abstract] [Full Text] [PDF]

				R. A. McClelland, D. Barrow, T.-A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. W. Gee, and R. I. Nicholson Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex) Endocrinology, July 1, 2001; 142(7): 2776 - 2788. [Abstract] [Full Text] [PDF]

				S. M. Henshall, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer Cancer Res., January 1, 2001; 61(2): 423 - 427. [Abstract] [Full Text]

				D. K. Biswas, A. P. Cruz, E. Gansberger, and A. B. Pardee Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells PNAS, July 18, 2000; 97(15): 8542 - 8547. [Abstract] [Full Text] [PDF]

				J. MacDougall and L. Matrisian Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes J. Cell Sci., January 2, 2000; 113(3): 409 - 423. [Abstract] [PDF]

				O. W. J. Prall, E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry Mol. Cell. Biol., August 1, 1998; 18(8): 4499 - 4508. [Abstract] [Full Text]